Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On January 19, 2023, John W. Hadden II, a member of the Board of Directors (the
"Board") of PLx Pharma, Inc. (the "Company"), resigned from the Board effective
immediately. Mr. Hadden's resignation is not the result of any disagreement with
the Company.
Item 8.01 Other Events.
In August 2022, and as previously disclosed, the Company engaged Raymond James &
Associates, Inc. as financial advisor to evaluate strategic alternatives to
maximize stockholder value. On January 14, 2023, the Company engaged
SierraConstellation Partners LLC, a business advisory firm, to further explore
strategic alternatives, which may include a liquidation strategy in the event
that more advantageous alternatives prove unavailable to the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data File (the cover page XBRL tags are
embedded within the Inline XBRL document).
© Edgar Online, source Glimpses